PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SignaBlok, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SignaBlok Awarded NIH Grant to Test New Therapy for Rheumatoid Arthritis - SignaBlok, Inc. was awarded a new $223,013 SBIR Phase I grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to develop a novel approach for targeted therapy of rheumatoid arthritis - SignaBlok.com
SignaBlok Awarded NIH Grant to Test New Therapy for Rheumatoid Arthritis

 

NewswireToday - /newswire/ - Shrewsbury, MA, United States, 2014/09/25 - SignaBlok, Inc. was awarded a new $223,013 SBIR Phase I grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to develop a novel approach for targeted therapy of rheumatoid arthritis - SignaBlok.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the National Institutes of Health (NIH), has awarded SignaBlok, Inc., a Massachusetts-based emerging biopharmaceutical company, a $223,013 Small Business Innovation Research (SBIR) Phase I grant to in vivo test a new targeted therapy of rheumatoid arthritis (RA).

SignaBlok’s innovative approach to RA therapy targets a specific receptor called TREM-1 that is expressed on inflammatory cells, macrophages, and serves as an inflammation amplifier. This receptor is critically involved in RA, cancer, sepsis and other inflammation-associated conditions.

The grant “Novel mechanism-based targeted approach to rheumatoid arthritis” combines two SignaBlok’s proprietary technologies: 1) ligand-independent inhibition of cell receptors using short synthetic peptides, known as the SCHOOL technology, and 2) nanotechnology for macrophage-targeted drug delivery.

The NIH funds will support development of macrophage-targeted nanoformulations that contain a TREM-1-specific SCHOOL peptide and their in vivo testing in an animal model of RA. The most promising formulations will be selected for Investigational New Drug (IND)-enabling studies and further clinical development. This could ultimately lead to first-in-class low-toxic therapies for RA, thereby improving RA treatment and decreasing long-term disability.

“This award from the NIAMS/NIH reinforces the promise of our SCHOOL technology and innovative drug delivery nanosystems,” said Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. “We have recently succeeded in the animal proof-of-concept (POC) testing of macrophage-targeted TREM-1-specific peptide nanoformulations in cancer and sepsis. With the NIAMS funding, we hope to establish animal POC for RA. This will set the stage for the development of new mechanism-based drugs with a broad spectrum of therapeutic indications."

References: 1) Sigalov AB. A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock. Int Immunopharmacol. 2014, 21:208-19; 2) Sigalov AB. Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages. Contrast Med Mol Imaging, 2014, in press.

About rheumatoid arthritis: RA is a chronic, systemic inflammatory disorder that causes chronic inflammation of the joints. RA affects about 1.5 million Americans and due to its severely debilitating nature costs society more than $40 billion each year. Despite advances in therapy, RA has no cure. This highlights the need for new treatments.

About SignaBlok

SignaBlok (signablok.com) is developing a new class of therapies SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SignaBlok, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SignaBlok Awarded NIH Grant to Test New Therapy for Rheumatoid Arthritis

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Alexander Sigalov - SignaBlok.com 
203-505-3807 sigalov[.]signablok.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SignaBlok, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SignaBlok, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)